WO2011078830A1

WO2011078830A1 - Rapidly dispersing effervescent formulation

Info

Publication number: WO2011078830A1
Application number: PCT/TR2010/000260
Authority: WO
Inventors: Bilgic Mahmut
Original assignee: Bilgic Mahmut
Priority date: 2009-12-25
Filing date: 2010-12-24
Publication date: 2011-06-30
Also published as: EP2515859A1; EP2515859B1

Abstract

Present invention is related to water dispersible pharmaceutical dosage forms comprising cefdinir as active agent and methods for preparation of these.

Description

RAPIDLY DISPERSING EFFERVESCENT FORMULATION

Present invention is related to effervescent pharmaceutical dosage forms comprising cefdinir as active agent and processes for preparation of these formulations.

Background of the invention Cefdinir molecule which is shown with Formula I was first disclosed in the patent numbered BE897864 and its chemical name is (6R,7R)-7-[[(2Z)-(2-amino-4- thiazolil)(hydroxyimino)acetyl] amino]-3-ethenyl-8-oxo-5-thia- 1 -azabicyclo[4.2.0]oct-2-en-2- carboxylic acid. The molecule, which is a third generation cephalosporin, is indicated for the treatment of several illnesses caused by gram positive and gram negative bacteria.

Formula I

Cefdinir which physically appears as a white powder has very poor solubility in common organic solvents such as methanol, ethanol, and acetonitrile and in water. Due to this property there are some problems while developing effervescent formulations comprising this molecule and in the bioavailability of the finished product. Depending on the formulation, some differences are seen in the physical properties of the finished product, for example some parameters such as hardness and dispersion time. Hardness of the tablets is important for carrying tablets without any breaking and using them safely; dispersion time is important for dispersing rapidly of effervescent product in water and getting the product ready for use in a short time. As the tablet gets harder, the fragility becomes lower but this effect the dispersion and dispersion becomes slower. This situation proves that in addition to all other physical properties of the pharmaceutical formulations (for instance; flowability and solubility of the formulation etc.), tablet hardness and dispersion time should be optimized sensitively.

Considering the prior art, it is seen that new formulations are required to prepare tablets for having optimum tablet hardness and dispersion time. The inventors have surprisingly found that the problems, which are present in the prior art, can be solved by effervescent cefdinir formulation according to the present invention.

Detailed description of the invention

The present invention is related to effervescent tablets which disperse in water in less than 120 seconds, preferably 120 seconds and comprise tablet hardness in the range of 7-8 kP and which comprise cefdinir as an active agent. Surprisingly, it was found that in effervescent formulations comprising cefdinir as an active agent, the formulation obtained by the use of polyvinyl pyrolidone in an amount in the range of 2-5% compared to the total weight of the unit dose, dispersed in a short time, that is less than 120 seconds, in water and the tablets obtained by using this formulation had the hardness of 7-8 kP. Therefore, effervescent tablet formulations which do not break during process and carrying and also dissolve in water rapidly were developed.

Accordingly, one aspect of the present invention is effervescent tablets which disperse in water in less than 120 seconds, preferably less than 110 seconds and have a tablet hardness of 7-8 kP and comprise cefdinir as an active agent. Another aspect of the present invention is the effervescent formulations comprising cefdinir as an active agent in which polyvinyl pyrolidone is used in an amount in the range of 2-5% compared to the total weight of the unit dose.

In the studies, it was seen that the use of polyvinyl pyrolidone plays an important role in obtaining the desired dispersion time and tablet hardness values. Several different substances can be used as a binder in the pharmaceutical formulations. The inventors selected polyvinyl pyrrolidone from these alternatives. Polyvinyl pyrrolidone is compared with the other binders which have similar structure to that of polyvinyl pyrolidone. The results of this comparison are represented in Table 1 and Table 2. In Table 1, the dissolution times of effervescent tablet formulations prepared by binders which are very similar to polyvinyl pyrolidone are shown. In tables, there are some data obtained from the use of hydroxypropyl cellulose (HPS), microcrystalline cellulose (MCC), hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP) and pregelatinized starch.

Each binder was added into the formulation in an amount of 4% of the weight of the unit dose and all the formulations are produced with the same production method. The results obtained indicates that binders providing the dissolution in a shortest time are HPS, PVP and pregelatinized starch. Table 1 : Dissolution time of the formulation comprising different binders.

The hardness values of the tablets formed by the effervescent formulations obtained by using different binders are illustrated in Table 2.

Tablo 2: Hardness values of the tablets obtained by the formulations comprising different binders.

As it is seen from these data, the formulations, in which the dissolution occurs in a short time and tablet hardness is not low, are obtained by using PVP as a binder.

Effervescent formulation in accordance with the present invention can be stored in tablet and/or sachet forms.

Effervescent formulation in accordance with the present invention comprises cefdinir, polyvinyl pyrrolidone and in addition to these, the other pharmaceutically acceptable excipients, for instance; basic agent, effervescent acid, effervescent base, sweetener, lubricant, coloring agent and flavoring agent. Cefdinir which can be used in effervescent formulation of the present invention can be present in the form of its solvates, hydrates, enetiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or as a combination of these.

Basic agent which can be used in the effervescent formulation of the present invention can be selected from a group of some basic agents comprising dibasic calcium phosphate, tribasic calcium phosphate, sodium carbonate, sodium hydrogen carbonate, trometamol, potassium carbonate, potassium hydrogen carbonate, potassium citrate, meglumine or combinations thereof. Basic agent which will be used in the formulation in accordance with the present invention is preferably selected from sodium carbonate, trometamol, dibasic calcium phosphate and meglumine. More preferably, trometamol is used.

Lubricant which can be used in the effervescent formulation according to the present invention can be selected from, but not limited with, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG6000, polyvinyl alcohol, potassium benzoate, sodium benzoate. Sweetener which can be used in effervescent formulation according to the present invention, can be selected from, but not limited with, a group comprising acesulfame, aspartamate, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharide, sodium saccharide, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof. Effervescent acid which can be used in according to the present invention, can be selected from organic acids such as citric acid, tartaric acid, malic acid, furmaric acid etc and effervescent base can be selected from basic agents such as sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate etc.

In effervescent formulations that will be produced by the process of the present invention, 1- 4000 mg of cefdinir or its pharmaceutically acceptable salts, hydrates, solvates and/or a combination of these in an amount equivalent to that can be used.

Another aspect of the present invention is that effervescent formulation comprising cefdinir includes compared to the total weight of the unit dose;

• 5-60% of cefidinir or solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms thereof and

• 1-30% organic base, • 2-5% polyvinyl pyrrolidone

• 0.1-5% lubricant

• 0.1 -5% sweetener

• 0.1-8% coloring agent and/or flavoring agent and · 0.1-90% effervescent couple

In the effervescent cefdinir formulation in accordance with the present invention, optionally a second active agent can be used. The second active agent can be selected from beta lactamase and cephalasporins, preferably clavulanic acid or combinations thereof.

Clavulanic acid used in the effervescent cefdinir formulation in accordance with the present invention, can be present in the form of its solvates, hydrates, enetiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or as a combination of these. Preferably, potassium clavulanate is used.

In the effervescent cefdinir formulation according to the present invention, optionally 50-500 mg of clavulanic acid or pharmaceutically acceptable salts, hydrates, solvates or a combination thereof in an amount equivalent to that can be used.

Clavulanic acid and/or derivatives thereof (for example potasium clavulanate) is very sensitive to moisture. Therefore, in the pharmaceutical composition according to the present invention, potasium clavulanate is preferably used together with a desiccant in a ratio of 1 : 1.

One or more than one of the following substances can be used as a desiccant; silica; colloid silica, for instance colloidal silica anhydrous, Aerosil® 200, magnesium trisilicate, powder cellulose, Cabosil®, magnesium oxide, calcium silicate, Syloid®, starch, microcrystalline cellulose and talk.

In the effervescent cefdinir formulation in accordance with the present invention, potasium clavulanate is preferably used with syloid or microcrystalline cellulose in a ratio of 1 : 1. In the effervescent cefdinir formulation in accordance with the present invention, compared to the total weight of the unit dose, 5-90%, preferably 10-80%, of clavulanic acid or pharmaceutically acceptable salts, solvates, hydrates or a combination thereof in an amount equivalent to that can be used. Another aspect of the present invention is the processes for the preparation of effervescent cefdinir formulations which disperse in water in less than 120 seconds, have a tablet hardness of 7-8 kP and comprise polyvinyl pyrrolidone in an amount in the range of 2-5%.

Said processes comprise the following steps;

• Granulation of cefdinir and effervescent base by aqueous solution of basic agent

• Mixing obtained granules with sweetener and effervescent acid and granulation of them with the solution comprising polyvinyl pyrrolidone in an amount in the range of 2-5%

• Finally, mixing obtained granules with coloring agent, flavoring agent, sweetener and lubricant, and optionally filling into the sachets or pressing them in tablet forms.

Though not limited by these examples, effervescent formulations in accordance with the present invention can be prepared according to the following examples.

EXAMPLE 1: Formulation and process for the preparation of effervescent tablet

Formulation, that will be prepared in accordance with the present invention, is obtained by granulation of sodium hydrogen carbonate and cefdinir with aqueous solution of organic base and then mixing the formed granules with citric acid and sweetener. The formed mixture is then granulated with a solution of polyvinyl pyrrolidone. The granule obtained after this step is mixed with lubricant, coloring agent, sweetener and flavouring agent and optionally it can be compressed as tablets. EXAMPLE 2: Formulation and process for the preparation of effervescent tablet

Formulation can be obtained by granulation of cefdinir with aqueous solution of organic base and then mixing the formed granules with sweetener, effervescent acid and potassium clavulanate: syloid. The formed mixture is then granulated with a solution of binder. The granule obtained after this step is mixed with lubricant, coloring agent, sweetener and flavouring agent and optionally it can be pressed as tablets.

In another aspect present invention relates to use of effervescent formulations comprising cefdinir and in addition to that pharmaceutically acceptable excipients for the treatment of infections caused by gram positive and gram negative bacteria.

In another aspect pharmaceutical formulation prepared in accordance with the present invention, is used for the manufacture of a medicament for use in the treatment and prophylaxis of upper respiratory tract infections such that ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis, lower respiratory tract infections such as pyelonephritis, cystitis and urethritis, skin and soft tissue infections such as froncle, pyoderma, impetigo and also gonorrhea and lyme diseases.

Claims

CLAIMS:

I . An effervescent formulation comprising cefdinir as an active agent, characterized in that said formulation comprises polyvinyl pyrrolidone in an amount in the range of 2-5% with respect to the total weight of the unit dose.

2. An effervescent formulation according to claim 1, wherein said formulation is in tablet or sachet form.

3. An effervescent formulation according to claim 2, wherein said formulation is preferably in tablet form.

4. An effervescent formulation according to claim 2, wherein said formulation disperse in water in less than 120 seconds.

5. An effervescent formulation according to claims 3 and 4, wherein the hardness of the tablet form is in the range of 7-8 kP.

6. An effervescent formulation comprising cefdinir according to claim 1, wherein said compoisition comprises pharmaceutically acceptable excipients, such as; basic agent, effervescent acid, effervescent base, sweetener, lubricant, coloring agent and flavoring agent etc. in addition to cefdinir and polyvinyl pyrolidone .

7. An effervescent formulation according to any of the previous claims, wherein cefdinir is present in the form of its solvates, hydrates, enetiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or as a combination thereof.

8. An effervescent formulation comprising cefdinir according to claim 6, wherein lubricant is selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.

9. An effervescent formulation comprising cefdinir according to claim 6, wherein sweetener is selected from a group comprising acesulfame, aspartamate, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharide, sodium saccharide, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.

10. An effervescent formulation comprising cefdinir according to claim 6, wherein effervescent acid is selected from organic acids such as citric acid, tartaric acid, malic acid, furmaric acid etc and effervescent base is selected from basic agents such as sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate etc.

I I . An effervescent formulation comprising cefdinir according to claim 6, wherein basic agent is selected from a group comprising dibasic calcium phosphate, tribasic calcium phosphate, sodium carbonate, sodium hydrogen carbonate, trometamol, potassium carbonate, potassium hydrogen carbonate, potassium citrate, meglumine.

12. An effervescent formulation comprising cefdinir according to claim 11, wherein basic agent is preferably selected from sodium carbonate, trometamol, dibasic calcium phosphate and meglumine.

13. An effervescent formulation comprising cefdinir according to claim 12, wherein trometamol is used as basic agent.

14. An effervescent cefdinir formulation prepared according to any of the previous claims, wherein said formulation comprises the followings compared to the total weight of the unit dose;

• 5-60% of cefidinir or its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms thereof and

• 1-30% organic base,

• 2-5% polyvinyl pyrrolidone · 0.1-5% lubricant

• 0.1-5% sweetener

• 0.1-8% coloring agent and/or flavoring agent and

• 0.1 -90% effervescent couple

15. An effervescent cefdinir formulation prepared according to any of the previous claims, wherein in addition to cefdinir, a second active agent selected from beta lactamase and/or cephalasporins is used.

16. A formulation according to claim 15, wherein clavulanic acid, preferably potassium clavulanate, is used as the second active agent.

17. A process that will be used in the production of a formulation according to claim 1, wherein said process comprises the following steps;

• Mixing the obtained granules with sweetener and effervescent acid and granulating them with the solution comprising polyvinyl pyrrolidone in an amount in the range of 2-5% • Finally, mixing obtained granules with coloring agent, flavoring agent, sweetener and lubricant, and optionally filling into the sachets or pressing them in tablet forms.

18. A formulation according to any of the previous claims, wherein said formulation is used in the manufacture of a medicament for use in the treatment and prophylaxis of upper respiratory tract infections such that ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis, lower respiratory tract infections such as pyelonephritis, cystitis and urethritis, skin and soft tissue infections such as froncle, pyoderma, impetigo and also gonorrhea and lyme diseases.